Trials / Recruiting
RecruitingNCT06301438
Dalpiciclib in HR+/HER2- ABC
Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 103 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dalpiciclib | dalpiciclib oral day 1-21, every 28 days |
Timeline
- Start date
- 2024-05-03
- Primary completion
- 2027-01-01
- Completion
- 2028-12-01
- First posted
- 2024-03-08
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06301438. Inclusion in this directory is not an endorsement.